Keros Therapeutics Inc [KROS] stock is trading at $59.79, up 2.96%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The KROS shares have gain 7.56% over the last week, with a monthly amount glided 31.84%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Keros Therapeutics Inc [NASDAQ: KROS] stock has seen the most recent analyst activity on September 23, 2024, when Guggenheim initiated its Buy rating and assigned the stock a price target of $96. Previously, Oppenheimer started tracking the stock with Outperform rating on June 25, 2024, and set its price target to $102. On February 21, 2024, William Blair initiated with a Outperform rating. Wells Fargo started tracking the stock assigning a Overweight rating and suggested a price target of $60 on December 08, 2023. Wedbush initiated its recommendation with a Outperform and recommended $86 as its price target on July 31, 2023. BofA Securities started tracking with a Buy rating for this stock on July 26, 2023, and assigned it a price target of $65. In a note dated February 14, 2023, Cowen initiated an Outperform rating.
Keros Therapeutics Inc [KROS] stock has fluctuated between $27.02 and $73.00 over the past year. Currently, Wall Street analysts expect the stock to reach $102 within the next 12 months. Keros Therapeutics Inc [NASDAQ: KROS] shares were valued at $59.79 at the most recent close of the market. An investor can expect a potential return of 70.6% based on the average KROS price forecast.
Analyzing the KROS fundamentals
Gross Profit Margin for this corporation currently stands at -4.1% with Operating Profit Margin at -696.15%, Pretax Profit Margin comes in at -620.13%, and Net Profit Margin reading is -620.13%. To continue investigating profitability, this company’s Return on Assets is posted at -0.37, Equity is -0.45 and Total Capital is -0.43. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.03.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 58.05 points at the first support level, and at 56.32 for the second support level. However, for the 1st resistance point, the stock is sitting at 60.72, and for the 2nd resistance point, it is at 61.66.
Ratios To Look Out For
For context, Keros Therapeutics Inc’s Current Ratio is 20.37. Also, the Quick Ratio is 20.37, while the Cash Ratio stands at 19.1. Considering the valuation of this stock, the price to sales ratio is 8308.60, the price to book ratio is 5.14.
Transactions by insiders
Recent insider trading involved GORDON CARL L, Director, that happened on Aug 13 ’24 when 0.25 million shares were sold. Director, ORBIMED ADVISORS LLC completed a deal on Aug 13 ’24 to sell 0.25 million shares. Meanwhile, Shareholder OrbiMed Genesis Master Fund, L bought 29400.0 shares on Aug 13 ’24.
